The infection with the hepatitis C virus (HCV) is an example of the translational research success. The reciprocal interactions between clinicians and scientists have allowed in 30 years the initiation of empirical treatments by interferon, the discovery of the virus, the development of serological and virological tools for diagnosis but also for prognosis (the non-invasive biochemical or morphological fibrosis tests, the predictors of the specific immune response including genetic IL28B polymorphisms). Finally, well-tolerated and effective treatments with oral antivirals inhibiting HCV non-structural viral proteins involved in viral replication have been marketed this last decade, allowing the cure of all infected subjects. HCV chronic infection, which is a public health issue, is a hepatic disease, which may lead to a cirrhosis and an hepatocellular carcinoma (HCC) but also a systemic disease with extra-hepatic manifestations either associated with a cryoglobulinemic vasculitis or chronic inflammation. The HCV infection is the only chronic viral infection, which may be cured: the so-called sustained virologic response, defined by undetectable HCV RNA 12 weeks after the end of the treatment, significantly reduces the risk of morbidity and mortality associated with hepatic and extra-hepatic manifestations, which are mainly reversible. The history of HCV ends with the pangenotypic efficacy of the multiple combinations, easy to use for 8–12 weeks with one to three pills per day and little problems of tolerance. This explains the short 30 years from the virus discovery to the viral hepatitis elimination policy proposed by the World Health Organization (WHO) in 2016.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis
Virology Journal Open Access 27 July 2021
Structural Chemistry Open Access 09 February 2021
Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology
BioDrugs Open Access 16 April 2020
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388:1081–88.
Cohen J. The scientific challenge of hepatitis C. Science. 1999;285:26–30.
Polaris Observatory, HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–76.
World Health Organization. Global hepatitis report. http://www.who.int/news-room/detail/27-07-2017-eliminate-hepatitis-who Organization WH. Geneva. 2017.
Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol. 2014;11:28–35.
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–62.
McGuinness PH, Bishop GA, Painter DM, Chan R, McCaughan GW. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology. 1996;23:676–87.
Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000;13:223–35.
Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506–10.
Kaito M, Watanabe S, Tsukiyama-Kohara K, Yamaguchi K, Kobayashi Y, Konishi M, et al. Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol. 1994;75:1755–60.
Gastaminza P, Dryden KA, Boyd B, Wood MR, Law M, Yeager M, et al. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol. 2010;84:10999–1009.
Dubuisson Jet, Cosset PP. Virology and cell biology of the hepatitis C virus life cycle: an update. J Hepatol. 2014;61:S3–S13.
Belouzard S, Cocquerel L, Dubuisson J. Hepatitis C virus entry into the hepatocyte. Cent Eur J Biol. 2011;6:933–45.
Brazzoli M, Bianchi A, Filippini S, Weiner A, Zhu Q, Pizza M, et al. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol. 2008;82:8316–29.
Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of Hepatitis C Virus to CD81. Science. 1998;282:938–41.
Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature. 2007;446:801–5.
Harris HJ, Farquhar MJ, Mee CJ, Davis C, Reynolds GM, Jennings A, et al. CD81 and claudin-1 coreceptor association: role in hepatitis C virus entry. J Virol. 2008;82:5007–20.
Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature. 2009;457:882–6183.
Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol. 2010;84:34–3.
Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med. 2011;17:589–95.
Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med. 2012;18:281–85.
Coller KE, Berger KL, Heaton NS, Cooper JD, Yoon R, Randall G. RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog. 2009;5:e1000702.
Blanchard E, Brand D, Trassard S, Goudeau A, Roingeard P. Hepatitis C virus-like particle morphogenesis. J Virol. 2002;76:4073–79.
Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C, et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol. 2006;80:6964–72.
Meertens L, Bertaux C, Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol. 2006;80:11571–78.
Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science. 2005;309:623–26.
Xu Z, Choi J, Lu W, Jing-hsiung Ou. Hepatitis C virus F protein is a short-lived protein associated with the endoplasmic reticulum. J Virol. 2003;77:1578–83.
Komurian-Pradel F, Rajoharison A, Berland JL, Khouri V, Perret M, Van Roosmalen M. Antigenic relevance of F protein in chronic hepatitis C virus infection. Hepatology. 2004;40:900–9.
Samrat SK, Li W, Singh S, Kumar R, Agrawal B. Alternate reading frame protein (F protein) of hepatitis C virus: paradoxical effects of activation and apoptosis on human dendritic cells lead to stimulation of T cells. PLoS ONE. 2014;9:e86567.
Arazi A, Sharabi A, Zinger H, Mozes E, Neumann AU. In vivo dynamical interactions between CD4 Tregs, CD8 Tregs and CD4+CD25- cells in mice. PLoS ONE. 2009;4:e8447.
Xu Z, Choi J, Yen TS, Lu W, Strohecker A, Govindarajan S, et al. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J. 2001;20:3840–48.
Paul P, Madan V, Bartenschlager R, Hepatitis C. Virus replication and assembly: living on the fat of the land. Cell Host Microbes. 2014;16:569–79.
Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. An overview of HCV molecular biology, replication and immune responses. Virol J. 2011;8:161–223.
Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5:453–63.
Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus rna abundance by a liver-specific microRNA. Science. 2005;309:1577–81.
Shimakami Tetsuro, Yamane Daisuke, Jangra RohitK, Kempf BrianJ, Spaniel Carolyn, Barton DavidJ, et al. Stabilization of hepatitis C virus RNA by an Ago2–miR-122 complex. Proc Natl Acad Sci USA. 2012;109:941–46.
Boulant S, Douglas MW, Moody L, Budkowska A, Targett-Adams P, McLauchlan J. et al. Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. Traffic. 2008;9:1268–82.
Bartenschlager R, Penin F, Lohmann V, André P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 2011;19:95–103.
Hueging K, Doepke M, Vieyres G, Bankwitz D, Frentzen A, Doerrbecker J, et al. Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. J Virol. 2014;88:1433–46.
Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M Jr, et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA. 2007;104:5848–53.
Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, Murayama A, et al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol. 2008;82:7964–76.
Scheel TKH, Rice CM. Understanding the hepatitis C virus life cycle paves the way for high effective therapies. Nat Med. 2013;19:837–49.
Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science. 1997;277:570–74.
Yanagi M, Purcell RH, Emerson SU, Bukh J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci USA. 1997;94:8738–43.
Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110–13.
Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol. 2002;76:13001–14.
Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science. 2000;290:1972–74.
Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005;11:791–96.
Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA. 2006;103:7408–13.
Murray EM, Grobler JA, Markel EJ, Pagnoni MF, Paonessa G, Simon AJ, et al. Persistent replication of hepatitis C virus replicons expressing the beta-lactamase reporter in subpopulations of highly permissive Huh7 cells. J Virol. 2003;77:2928–35.
Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem. 2003;278:41624–30.
Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology. 2009;49:364–77.
Morozov VA, Lagaye S. Hepatitis C virus: morphogenesis, infection and therapy. World J Hepatol. 2018;10:186–212.
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–93.
Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004;3:8.
Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aubé C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology. 1997;113:1609–16.
Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–50.
Cassinotto C, Lapuyade B, Mouries A, Hiriart JB, Vergniol J, Gaye D, et al. Non-invasive assessment of liver fibrosis with impulse elastography: comparison of Supersonic Shear Imaging with ARFI and FibroScan(R). J Hepatol. 2014;61:550–57.
Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355:2444–51.
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–93.
Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis. 2006;194:895–03.
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–01.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–01.
McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010;138:2307–14.
Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, Cisper N, et al. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood. 2009;113:5868–77.
Freeman AJ, Pan Y, Harvey CE, Post JJ, Law MG, White PA, et al. The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection. J Hepatol. 2003;38:349–56.
Bochud PY, Bibert S, Kutalik Z, Patin E, Guergnon J, Nalpas B. et al. Swiss Hepatitis C Cohort Study Group, ANRS HC EP 26 Genoscan Study Group. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology. 2012;55:384–94.
Trinchet JC, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology. 2015;62:737–50.
Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018;67:2025–234.
Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney. Nat Rev Nephrol. 2019;15:73–86.
Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149:1345–60.
Pozzato G, Mazzaro C, Dal Maso L, Mauro E, Zorat F, Moratelli G, et al. Hepatitis C virus and non- Hodgkin’s lymphomas: meta- analysis of epidemiology data and therapy options. World J Hepatol. 2016;8:107–16.
Pol S, Vallet-Pichard A, Hermine O. Extra-hepatic cancers and HCV. Nat Rev Gastroenterol Hepatol. 2018;15:283–90.
Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469–77.
Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495–03.
Spengler U, Nattermann J. Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci (Lond). 2007;112:141–55.
Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol. 1992;149:3339–44.
Schirren CA, Jung MC, Gerlach JT, Worzfeld T, Baretton G, Mamin M, et al. Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma. Hepatology. 2000;32:597–03.
Alatrakchi N, Koziel M. Regulatory T cells and viral liver disease. J Viral Hepat. 2009;16:223–29.
Buhler S, Bartenschlager R. New targets for antiviral therapy of chronic hepatitis C. Liver Int. 2012;32:19–16.
Fontaine H, Chaix ML, Lagneau JL, Brechot C, Pol S. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa. Lancet. 2000;356:41.
Parlati L, Sirmai L, Dupuy CA, Glotz D, Pol S. Evidence of HCV recovery after therapy of hepatitis C virus infection by direct acting antivirals. Clin Res Hepatol Gastroenterol. 2018;S2210-7401:30183–9. https://doi.org/10.1016/j.clinre.2018.09.002. pii
AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. 2017 http://www.hcvguidelines.org. Accessed 16 July 2017.
European Association for the Study of the Liver. EASL Recommendations on Treatment of hepatitis C 2016. J Hepatol. 2017;66:153–94.
Pol S, Carnot F, Nalpas B, Lagneau JL, Fontaine H, Serpaggi J. Reversibility of hepatitis C virus- related cirrhosis. Hum Pathol. 2004;35:107–12.
Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008;149:399–03.
Hermine O, Lefrère F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89–94.
Mahale P, Engels EA, Li R, Torres HA, Hwang LY, Brown EL, et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut. 2018;67:553–61.
Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, et al. ANRS CO12 CirVir group. Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. Am Heart J. 2018;198:4–17.
Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D. et al. ANRS CO12 CirVir Group. Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs. Gastroenterology. 2018;155:1436–50.
Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode Ch. et al. Clinical outcomes in patients with chronic hepatitis C following direct-acting antiviral therapy: a prospective cohort study. Lancet. 2019;393:1453–64.
Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P. et al. ANRS CO12 CirVir Group. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152:142–56.
Petta S, Macaluso FS, Craxi A. Cardiovascular diseases and HCV infection: a simple association or more? Gut. 2014;63:369–75.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–65.
Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V.et al. CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59:434–41.
Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354–69.
Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2018;153:113–22.
Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. High SVR rates upon 8- or 12-week treatment with glecaprevir and pibrentasvir in patients with chronic HCV genotype 1–6 infection without cirrhosis. J Hepatol. 2017;67:263–71.
Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1–6 patients without cirrhosis. J Hepatol. 2018;69:293–300.
Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134–46.
Boerekamps A, van den Berk GE, Lauw FN, Leyten EM, van Kasteren ME, van Eeden A, et al. Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus positive men who have sex with men after unrestricted access to HCV therapy. Clin Infect Dis. 2018;66:1360–65.
Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016;15:683–94.
O’Shaughnessy MM, O’Regan JA, Murray FE, Connell JA, Duffy MP, Francis VM, et al. Re-infection following sustained virological response with a different hepatitis C virus genotype: implications for infection control policy. Clin Kidney J. 2012;5:250–53.
Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2012;58:792–800.
Razavi H, Robbins S, Zeuzem S, Negro F, Buti M, Duberg AS, et al. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:325–36.
Lazarus JV, Wiktor S, Colombo M, Thursz M. EASL International Liver Foundation. Micro-elimination—a path to global elimination of hepatitis C. J Hepatol. 2017;67:665–66.
Conflict of interest
SP has received consulting and lecturing fees from Bristol-Myers Squibb, Janssen, Gilead, MSD, Abbvie and grants from Bristol-Myers Squibb, Gilead, Roche and MSD. The remaining author declares that she has no conflict of interest.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Pol, S., Lagaye, S. The remarkable history of the hepatitis C virus. Genes Immun 20, 436–446 (2019). https://doi.org/10.1038/s41435-019-0066-z
This article is cited by
Is there a connection between neurocognitive profile in treatment naïve non-cirrhotic HCV patients and level of systemic inflammation?
Journal of NeuroVirology (2023)
Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis
Virology Journal (2021)
Structural Chemistry (2021)
Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study
BMC Gastroenterology (2020)
Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology